344-39-8

Basic information

• Product Name: 4-METHOXY-1-NITRO-2-TRIFLUOROMETHYL-BENZENE
• Synonyms: 4-METHOXY-1-NITRO-2-TRIFLUOROMETHYL-BENZENE;4-Nitro-3-(trifluoromethyl)anisole;1-Methoxy-4-nitro-3-(trifluoromethyl)benzene;5-Methoxy-2-nitrobenzotrifluoride 98%;Benzene,4-Methoxy-1-nitro-2-(trifluoroMethyl)-;5-Methoxy-2-nitrobenzotrifluoride98%
• CAS NO: 344-39-8
• Molecular Formula: C₈H₆F₃NO₃
• Molecular Weight: 221.1333496
• Product Categories: Trifluoromethyl-benzene series
• Mol File: 344-39-8.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 275.7 °C at 760 mmHg
• Flash Point: 120.5 °C
• Appearance: /
• Density: 1.392
• Vapor Pressure: 0.00844mmHg at 25°C
• Refractive Index: 1.471
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 4-METHOXY-1-NITRO-2-TRIFLUOROMETHYL-BENZENE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-METHOXY-1-NITRO-2-TRIFLUOROMETHYL-BENZENE(344-39-8)
• EPA Substance Registry System: 4-METHOXY-1-NITRO-2-TRIFLUOROMETHYL-BENZENE(344-39-8)

Safety Data

• Hazardous Substances Data: 344-39-8(Hazardous Substances Data)

Usage

Uses

4-Methoxy-1-nitro-2-(trifluoromethyl)benzene

InChI:InChI=1/C8H6F3NO3/c1-15-5-2-3-7(12(13)14)6(4-5)8(9,10)11/h2-4H,1H3

Upstream product

• 88-30-2 3-trifluoromethyl-4-nitrophenol 
• 74-88-4 methyl iodide 
• 98-17-9 3-Trifluoromethylphenol 
• 67-56-1 methanol 
• 118-83-2 5-chloro-2-nitrotrifluoromethylbenzene 
• 393-09-9 4-fluoro-1-nitro-2-trifluoromethyl-benzene 

Downstream Products

• 53903-49-4 4-methoxy-2-(trifluoromethyl)benzenamine 
• 1621254-68-9 5'-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-3,4'-dimethoxy-2'-(trifluoromethyl)biphenyl-4-carboxylic acid 
• 1621254-67-8 5'-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-3-chloro-4'-methoxy-2'-(trifluoromethyl)biphenyl-4-carboxylic acid 
• 1621254-72-5 methyl 5'-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-3,4'-dimethoxy-2'-(trifluoromethyl)biphenyl-4-carboxylate 
• 1621254-71-4 methyl 5'-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-3-chloro-4'-methoxy-2'-(trifluoromethyl)biphenyl-4-carboxylate 
• 1621254-54-3 5'-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4'-methoxy-2-methyl-2'-(trifluoromethyl)biphenyl-4-carboxylic acid 
• 1621254-53-2 5'-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-2-chloro-4'-methoxy-2'-(trifluoromethyl)biphenyl-4-carboxylic acid 
• 1621254-52-1 5'-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-3-fluoro-4'-methoxy-2'-(trifluoromethyl)biphenyl-4-carboxylic acid 
• 1621254-51-0 5'-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-2-fluoro-4'-methoxy-2'-(trifluoromethyl)biphenyl-4-carboxylic acid 
• 1621254-50-9 5'-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4'-methoxy-2'-(trifluoromethyl)biphenyl-4-carboxylic acid 
• 1621254-47-4 methyl 5'-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4'-methoxy-2-methyl-2'-(trifluoromethyl)biphenyl-4-carboxylate 
• 1621254-46-3 methyl 5'-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-2-chloro-4'-methoxy-2'-(trifluoromethyl)biphenyl-4-carboxylate 
• 1621254-45-2 ethyl 5'-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-3-fluoro-4'-methoxy-2'-(trifluoromethyl)biphenyl-4-carboxylate 
• 1621254-44-1 methyl 5'-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-2-fluoro-4'-methoxy-2'-(trifluoromethyl)biphenyl-4-carboxylate 

Relevant articles and documents

Activation and stabilization of aldimines by an ortho-trifluoromethyl substituent in direct vinylogous Mannich-type reactions

Lewis acid catalyzed direct vinylogous Mannich-type reaction with a weak nucleophile dienol, generated in situ by ring-opening and rearrangement of vinyloxiranes, could be demonstrated in excellent yields under mild conditions using benzylidene(4-methoxy-2-trifluoromethyl)aniline (MTMA) as an electrophile. The o-trifluoromethyl substituent can stabilize imines by a steric effect and activate by an electron-withdrawing effect. It proved to be an easily deprotectable protecting group for direct Mannich-type reactions.

TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS

The present invention relates to tricyclic compounds of formula (I) or pharmaceutically acceptable salt thereof as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthama, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases. (I)

Structure-Activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating mycobacterium tuberculosis

Tuberculosis (TB) remains as a global pandemic that is aggravated by a lack of health care, the spread of HIV, and the emergence of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDRTB) strains. New anti-TB drugs are urgently required to shorten the long 6-12 month treatment regimen and to battle drug-resistant Mtb strains. We have identified several potent quinoline-based anti-TB compounds, bearing an isoxazole containing side-chain. The most potent compounds, 7g and 13, exhibited submicromolar activity against the replicating bacteria (R-TB), with minimum inhibitory concentrations (MICs) of 0.77 and 0.95 μM, respectively. In general, these compounds also had micromolar activity against the nonreplicating persistent bacteria (NRP-TB) and did not show toxicity on Vero cells up to 128 μM concentration. Compounds 7g and 13 were shown to retain their anti-TB activity against rifampin, isoniazid, and streptomycin resistant Mtb strains. The results suggest that quinoline-isoxazole-based anti-TB compounds are promising leads for new TB drug development.